7210 Wareham Drive, Tampa, FL 33647
May 6, 2025 WW management reported first quarter 2025 results today. “We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth,” said Tara Comonte, President and CEO. “As the weight management landscape evolves, we believe our unique combination of science-backed behavioral support, […]
Weight Watchers Reports Q1 Results Read More »
May 1, 2025 The National Consumers League (NCL) – a leading non-profit fighting fraud in the marketplace – today released a white paper as a blueprint for policy changes to combat the flood of false information circulating online about GLP-1 products and launched an ambitious national anti-disinformation effort called the Weight Truth with the online
April 29, 2025 WW announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part of WeightWatchers’ holistic approach to weight management, the integration will streamline access to
Weight Watchers Streamlines Member Access to Zepbound® Vials Read More »
April 28, 2025 According to CEO Dan Chard: “This year, we are focused on revitalizing our coach and customer base by supporting them with enhanced tools, data, and new products. Our business focus remains on reestablishing sustainable long-term growth while improving profitability.” First quarter 2025 revenue decreased 33.8% to $115.7 million from $174.7 million for the
Medifast Reports First Quarter Results – Slide Continues Read More »
April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest
Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »
April 17, 2025 New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6%
Eli Lilly’s New Weight Loss Pill Shows Promise Read More »
April 12, 2025 We noticed a post on Instagram today that pitches a company that will set up a medical weight loss program, using GLP-1 drugs for gyms. We shouldn’t be surprised. Everyone else has entered the GLP-1 gold rush, including med spas, so why not gyms as well? The company offering this “opportunity” is
Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded Read More »
March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can
FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »
March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, has updated its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think 2025
Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »
March 5, 2025 Weight loss drugs (GLP-1s) have soared in popularity over the last two years, with about 12% of American adults reporting that they’ve used a medication like Ozempic, Wegovy or Mounjaro to slim down. That’s a big slice of the population — and new research shows that being on these medications influences what
GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits Read More »